Science & Enterprise subscription

Follow us on Twitter

  • Researchers in the U.S. and China designed a hydrogel patch that in lab animals reduces the damage to heart muscle… https://t.co/UBLOpWcHuJ
    about 2 hours ago
  • New post on Science and Enterprise: Repair Patch Devised for Heart Attacks https://t.co/KfUKGAiRVr #Science #Business
    about 2 hours ago
  • An experimental treatment using a person's modified T-cells from the immune system to attack solid tumor cancers re… https://t.co/gP2T528cvQ
    about 20 hours ago
  • New post on Science and Enterprise: Patent Awarded for Engineered T-Cell Cancer Therapy https://t.co/2sVFALStqh #Science #Business
    about 20 hours ago
  • A biotechnology team uses genome-editing to create synthetic genes acting like electronic circuits that can be arr… https://t.co/TXWIwHqP6w
    about 1 day ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Biopharm Starts Genetic Heart Disease Clinical Database

Heart angiogram

(NASA.gov)

14 May 2014. MyoKardia Inc., a biopharmaceutical company in South San Francisco, California, began a repository of clinical data on patients with genetic heart disorders. The database, known as Sarcomeric Human Cardiomyopathy Registry, or SHaRe, is a joint project with seven medical centers specializing in these conditions in the U.S., U.K., Netherlands, and Italy.

SHaRe aims to collect de-identified clinical and lab data from patients at these institutions with hypertrophic cardiomyopathy or dilated cardiomyopathy, disorders that result from mutations in protein genes of muscles used in heart contractions. With hypertrophic cardiomyopathy, heart muscles become abnormally thick, making it more difficult for the heart to pump blood. In dilated cardiomyopathy, the heart’s left ventricle — the main pumping chamber — becomes enlarged, resulting in less pumping force than a healthy heart.

MyoKardia develops small molecule therapies that address the underlying genetic nature of these disorders, which the company says affects some 800,000 people in the U.S.  Both hypertrophic cardiomyopathy and dilated cardiomyopathy, the company notes, can result from varying genetic mutations, and be expressed in different physical traits or conditions. As a result, a database like SHaRe can help clinicians and researchers better understand the interactions among these mutations and traits that can lead to more targeted therapies based on the genetics of individual patients.

Hospitals taking part in SHaRe are Brigham and Women’s Hospital in Boston, University of Michigan Medical Center, Stanford University Medical Center, Boston Children’s Hospital, The Heart Hospital at University College London in the U.K., Florence Centre for Cardiomyopathies in Italy, and Erasmus University Medical Center in the Netherlands. The repository already accumulated data on more than 6,800 individuals, both patients and family members.

MyoKardia was started in 2012 by four academic researchers in heart muscle biology and cardiovascular genetics from Harvard Medical School, Brigham and Women’s Hospital, and University of Colorado. The company received its initial financing of $38 million from Third Rock Ventures, a life sciences venture capital firm.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.